Crown Bioscience is a cutting edge translational technology company providing drug discovery and preclinical development services in the areas of oncology, immunology, inflammation, cardiovascular, and metabolic disease. We bring clarity to drug discovery and enable clients around the world to deliver superior clinical candidates. Our premier translational platforms for cancer, inflammation, and metabolic disease help our clients accelerate their new drug development programs.
The Jackson Laboratory is a leading provider of cancer mouse models and in vivo oncology services and a National Cancer Institute designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customizable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanized mouse models for immuno-oncology drug development.
For the past 20 years, genOway has aimed to improve the predictability and reliability of preclinical data by designing models of high physiological relevancy to best meet researchers’ needs. With a catalog of humanized immune checkpoint mouse models, and mice featuring the human immune system, genOway possesses a broad set of tools to help decipher the mechanism of action as well as the efficacy and safety of drugs targeting the immune system. Additionally, genOway owns strong intellectual property rights, combining patents and licensing agreements, enabling the company to provide end users the necessary freedom to operate.
Biocytogen is a global one-stop drug discovery solution provider with operations in the US and China. Empowered by its cutting-edge gene editing technologies and state-of-art animal facility, Biocytogen developed a seamlessly integrated platform for efficient antibody drug discovery. The technical teams in Biocytogen support a comprehensive portfolio of products and services, covering in vivo/in vitro preclinical services, humanized models for immuno-oncology and autoimmune diseases, fully human antibody (via RenMab™ Mouse), therapeutic antibody discovery and development services, CMC/CDMO, and regulatory affairs support. Biocytogen collaborates with more than 70% of top 50 pharmaceutical and numerous biotech start-up companies worldwide.
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process and significantly reduces its costs. INOVOTION has developed a unique technology dedicated to early in vivo EFFICACY and TOXICITY evaluation of anti-cancer drugs.
Preclinical oncology solutions business of Covance. Access a comprehensive range of in vitro and in vivo preclinical oncology pharmacology services now available within Covance. You can progress your oncology therapeutic through all phases of research and development with Covance’s end-to-end solutions.
Hera Biolabs, Inc., is an innovative pre-clinical CRO utilizing cuttingedge gene-editing technologies to create novel in vivo models for oncology. Given our mission to accelerate cancer research and rug development, we focus upon rat models to deliver translationallyrelevant, high-quality results. Using proprietary technologies. Our first SRG model is the OncoRat®, uniquely suited for xenograft studies given its excellent tumor take-rates and ability to deliver masses 10x that of mouse models in half the time – all without the increased risk of genetic drift from multiple passages as observed in mice.
VisualSonics is the world’s leading developer of high-resolution, ultrasound-based, in vivo microimaging systems designed specifically for non-invasive preclinical research. The company’s enabling technology allows researchers at the world’s most prestigious pharmaceutical and biotechnology companies, hospitals and universities to conduct research in cardiovascular, cancer, and developmental biology areas. The technology supports applications that include genetic research, phenotypic studies and drug development.
ProQinase is a leading contract research organization for discovery of conventional and immune-modulating drugs in oncology. As an innovation driver in the area of immuno-oncology, we will introduce SubQPerior, an implantation method to overcome common issues such as heterogeneity and ulceration in subcutaneous tumor models. We have partnered with Reaction Biology, an early stage drug discovery CRO, to provide our customers with a full suite of services for targeted and phenotypic drug discovery approaches. Let’s discover together.
Human Metabolome Technologies (HMT) is a metabolomics company since 2003 focused on solutions for the biomedical industry and academia. HMT uses CE-MS and LC-MS technologies to perform quantitative and non-quantitative metabolite identification for biomarker discovery in oncology, neurobiology, cardiovascular and other diseases. Our CARCINOSCOPE™ platform is especially designed to address research in cancer with quantitative measurements of the glycolytic, amino acid, urea, glutathione, and TCA pathways in cancer cells and tissues. Our Dual Scan techniques address both small molecule and lipid profiling in tumor tissue and biofluids.